[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606457":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":80,"overallStatus":90,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Hartford HealthCare","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bariatric Surgery",null,"Patients who plan to undergo bariatric surgery",[13],"Procedure: Bariatric Surgery",{"label":15,"type":10,"description":16,"interventionNames":17},"GLP1 or GLP1\u002FGIP1","Patients who plan to take GLP1 or GLP1\u002FGIP1 medications",[18],"Drug: GLP1 receptor agonist",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":10},"PROCEDURE","Patients in this arm plan to undergo gastric sleeve or gastric bypass surgery.",[9],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DRUG","GLP1 receptor agonist","Patients in this arm plan to start a GLP-1 receptor agonist.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Madeline Carmain, MD","CONTACT","860.972.4338","madeline.carmain@hcchealth.org",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hartford Hospital","Hartford","Connecticut","06106","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-72.68509,41.76371,{"lat":47,"lon":46},[50],{"name":31,"role":32,"phone":51,"phoneExt":10,"email":34},"860-972-4338",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Madeline Carmain","Fellow, Urogynecology","100606457","pelvic-floor-disorder-symptoms-in-women-seeking-weight-loss-therapy-100606457",false,"NCT07175805","Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy","Inclusion Criteria:\n\n* female\n* 18-89 years old\n* any race\u002Fethnicity\n* BMI ≥30 kg\u002Fm2\n* current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \\& Bariatric Surgery\n* able\u002Fwilling to give informed consent\n* have a home scale to measure weight\n\nPatients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm:\n\n* prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1\u002Fgastric inhibitory peptide (GIP1)\n* taking other weight loss agents (such as metformin)\n\nPatients meeting all the following criteria will be eligible to participate in the bariatric surgery arm:\n\n* plan to undergo gastric sleeve or gastric bypass surgery\n* taking weight loss agents which are not GLP-1 RA or GLP-1\u002FGIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1\u002FGIP1 medications after surgery.\n\nExclusion Criteria:\n\n* Pregnant\n* ≥90 years old\n* \\\u003C18 years old\n* BMI \\\u003C30 kg\u002Fm2\n* A history of bariatric surgery prior to enrollment\n* No home scale to measure weight\n* Active cancer",true,"FEMALE","18 Years","90 Years",{"count":67,"type":68},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.",[72,73,74,75,76,77,78,9,79],"Lower Urinary Tract Symptoms","Stress Urinary Incontinence","Urge Urinary Incontinence","Overactive Bladder","Pelvic Organ Prolapse","Weight Loss","Fecal Incontinence","glp1 Agonist",[81,82,83,84,85,86,87,88,89],"lower urinary tract symtpoms","stress urinary incontinence","urge urinary incontinence","overactive bladder","pelvic organ prolapse","weight loss","fecal incontinence","bariatric surgery","glp1 agonist","NOT_YET_RECRUITING","2025-09-15",{"date":93,"type":94},"2025-09-16","ACTUAL",{"date":96,"type":68},"2025-10",{"date":98,"type":68},"2027-06",{"name":5,"class":6},1]